Impact of ETI Therapy on Systemic Inflammation and Lung Function in Cystic Fibrosis
发布者：Unknown
·发布于: 2025-12-13
Discussion regarding how the triple CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) influences systemic inflammation biomarkers and analyzing their correlation with lung function improvements in individuals with cystic fibrosis.